Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

被引：128

作者：

Rose, JW

Watt, HE

White, AT

Carlson, NG

机构：

[1] VASLSHCS, Neurovirol Res Lab, Salt Lake City, UT 84148 USA

[2] Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA

[3] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT 84112 USA

[4] VASLSHCS, Dept Geriatr Res & Clin Ctr, Salt Lake City, UT 84148 USA

来源：

ANNALS OF NEUROLOGY | 2004年 / 56卷 / 06期

关键词：

D O I：

10.1002/ana.20287

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin-2 receptor alpha chain, was safe and efficacious in relapsing-remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity.

引用

收藏

页码：864 / 867

页数：4

相关论文

共 10 条

[1] Current immunotherapy for demyelinating diseases [J].

Bashir, K ;

Whitaker, JN .

ARCHIVES OF NEUROLOGY, 2002, 59 (05) :726-731

[2] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[3] IMMUNOTHERAPY OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) - DIFFERENTIAL EFFECT OF ANTI-IL-2 RECEPTOR ANTIBODY THERAPY ON ACTIVELY INDUCED AND T-LINE MEDIATED EAE OF THE LEWIS RAT [J].

ENGELHARDT, B ;

DIAMANTSTEIN, T ;

WEKERLE, H .

JOURNAL OF AUTOIMMUNITY, 1989, 2 (01) :61-73

[4]

HAYOSH NS, 1987, J IMMUNOL, V138, P3771

[5] Advances in interleukin 2 receptor targeted treatment [J].

Morris, JC ;

Waldmann, TA .

ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :109-114

[6] Medical progress: Multiple sclerosis. [J].

Noseworthy, JH ;

Lucchinetti, C ;

Rodriguez, M ;

Weinshenker, BG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :938-952

[7] Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial [J].

Nussenblatt, RB ;

Fortin, E ;

Schiffman, R ;

Rizzo, L ;

Smith, J ;

Van Veldhisen, P ;

Sran, P ;

Yaffe, A ;

Goldman, CK ;

Waldmann, TA ;

Whitcup, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7462-7466

[8] CHIMERIC CYTOTOXIN IL2-PE40 INHIBITS RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS [J].

ROSE, JW ;

LORBERBOUMGALSKI, H ;

FITZGERALD, D ;

MCCARRON, R ;

HILL, KE ;

TOWNSEND, JJ ;

PASTAN, I .

JOURNAL OF NEUROIMMUNOLOGY, 1991, 32 (03) :209-217

[9] Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation [J].

Vincenti, F ;

Kirkman, R ;

Light, S ;

Bumgardner, G ;

Pescovitz, M ;

Halloran, P ;

Neylan, J ;

Wilkinson, A ;

Ekberg, H ;

Gaston, R ;

Backman, L ;

Burdick, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (03) :161-165

[10]

Waldmann Thomas A., 2000, Hematology Am Soc Hematol Educ Program, P394